Serum metabolomics of hyperbilirubinemia and hyperuricemia in the Tibetan plateau has unique characteristics.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
received:
22
04
2023
accepted:
03
08
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Few studies have provided data on the metabolomics characteristics of metabolic diseases such as hyperuricemia and hyperbilirubinemia in the Tibetan plateau. In the current study, we sought to investigate the serum metabolomics characteristics of hyperbilirubinemia and hyperuricemia in the Tibetan plateau, with the aim to provide a basis for further research on their pathogenesis, prevention, and treatment. The study participants were born in low-altitude areas below 1000 m and had no prior experience living in a high-altitude area before entering Golmud, Tibet (average elevation: 3000 m) and Yushu, Qinghai (average elevation: 4200 m). Thirty-four participants with hyperbilirubinemia (18 in Golmud and 16 in Yushu), 24 participants with hyperuricemia, and 22 healthy controls were enrolled. The serum samples of subjects were separated and then sent to a local tertiary hospital for biochemical examination. Serum widely targeted technology, based on the ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) platform, was used to detect serum metabolites and differential metabolites. Compared to the healthy controls, hyperbilirubinemia patients from Golmud showed 19 differential metabolites, hyperbilirubinemia patients from Yushu showed 12 differential metabolites, and hyperuricemia patients from Yushu showed 23 differential metabolites. Compared to the hyperbilirubinemia patients from Golmud that is at a low altitude, the Yushu groups had 33 different metabolites. Differential metabolites are primarily classified into amino acids and their derivatives, nucleotides and their derivatives, organic acids and their derivatives, and lipids/fatty acids. These are related to metabolic pathways such as caffeine metabolism, arachidonic acid metabolism, and tyrosine metabolism. Hyperbilirubinemia and hyperuricemia in the Tibetan plateau have unique serum metabolomics characteristics. Glycine derivatives and arachidonic acid and its derivatives were associated with plateau hyperbilirubinemia, and vanillic acid and pentadecafluorooctanoic acid were associated with plateau hyperuricemia.
Identifiants
pubmed: 37550384
doi: 10.1038/s41598-023-40027-6
pii: 10.1038/s41598-023-40027-6
pmc: PMC10406831
doi:
Substances chimiques
Arachidonic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12772Informations de copyright
© 2023. Springer Nature Limited.
Références
Front Physiol. 2022 Sep 06;13:994469
pubmed: 36148300
J Biol Chem. 2003 Jun 27;278(26):24153-63
pubmed: 12676927
Blood. 2011 Nov 17;118(20):5701-12
pubmed: 21841162
Cardiovasc Toxicol. 2011 Mar;11(1):58-66
pubmed: 21161433
Life Sci. 2010 Aug 14;87(7-8):223-31
pubmed: 20619278
Diabetol Int. 2016 Sep 21;7(4):338-341
pubmed: 30603284
Eur Respir Rev. 2017 Jan 31;26(143):
pubmed: 28143879
High Alt Med Biol. 2009 Fall;10(3):269-74
pubmed: 19775217
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Jun;1863(6):651-656
pubmed: 29555597
J Biol Chem. 2001 Apr 27;276(17):14359-65
pubmed: 11278616
Hepatology. 2018 Apr;67(4):1609-1619
pubmed: 29059457
Cells. 2021 Feb 28;10(3):
pubmed: 33671004
Biomed Res Int. 2020 Jun 26;2020:5817348
pubmed: 32685502
Eur J Appl Physiol. 2012 Aug;112(8):2923-32
pubmed: 22143846
Am J Physiol Endocrinol Metab. 2020 Nov 1;319(5):E827-E834
pubmed: 32893671
Oxid Med Cell Longev. 2020 Apr 20;2020:8348035
pubmed: 32377308
Adv Sci (Weinh). 2022 Apr;9(11):e2103982
pubmed: 35138033
Exp Dermatol. 2010 Aug;19(8):742-50
pubmed: 20482617
Respir Physiol Neurobiol. 2007 Sep 30;158(2-3):128-31
pubmed: 17482529
Trends Endocrinol Metab. 2018 Mar;29(3):140-150
pubmed: 29409713
Physiol Rev. 2020 Jul 1;100(3):1291-1346
pubmed: 32401177
J Surg Res. 2017 May 1;211:14-20
pubmed: 28501110
Mol Cell Endocrinol. 2012 Jul 6;358(1):88-95
pubmed: 22502743
Hum Exp Toxicol. 2018 Feb;37(2):135-141
pubmed: 29233001
Mol Med Rep. 2016 Jan;13(1):753-61
pubmed: 26647763
Biomed Pharmacother. 2018 Dec;108:325-330
pubmed: 30227325
Antioxidants (Basel). 2022 Jan 28;11(2):267
pubmed: 35204150
J Matern Fetal Neonatal Med. 2017 Oct;30(19):2297-2300
pubmed: 27724130
mSystems. 2020 Jan 21;5(1):
pubmed: 31964769
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
Int J Mol Sci. 2022 Mar 16;23(6):
pubmed: 35328614
J Lipid Res. 2009 Mar;50(3):521-533
pubmed: 18849464
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Environ Pollut. 2022 Sep 15;309:119756
pubmed: 35839969
High Alt Med Biol. 2018 Mar;19(1):4-6
pubmed: 29583031
Biol Pharm Bull. 2009 Jul;32(7):1215-9
pubmed: 19571388
High Alt Med Biol. 2006 Spring;7(1):47-53
pubmed: 16544966
Blood. 2008 Jun 15;111(12):5581-91
pubmed: 18408167
Antioxidants (Basel). 2022 Jan 18;11(2):
pubmed: 35204062